Abnormal accumulation of aggregated α-synuclein (aSyn) is a hallmark of sporadic and familial Parkinson's disease (PD) and related synucleinopathies. Recent studies suggest a neuroprotective role of adenosine A 2A receptor (A 2A R) antagonists in PD. Nevertheless, the precise molecular mechanisms underlying this neuroprotection remain unclear. We assessed the impact of A 2A R blockade or genetic deletion (A 2A R KO) on synaptic plasticity and neuronal cell death induced by aSyn oligomers. We found that impairment of LTP associated with aSyn exposure was rescued in A 2A R KO mice or upon A 2A R blockade, through an NMDA receptor-dependent mechanism. The mechanisms underlying these effects were evaluated in SH-SY5Y cells overexpressing aSyn and rat primary neuronal cultures exposed to aSyn. Cell death in both conditions was prevented by selective A 2A R antagonists. Interestingly, blockade of these receptors did not interfere with aSyn oligomerization but, instead, reduced the percentage of cells displaying aSyn inclusions. Altogether, our data raise the possibility that the well-documented effects of A 2A R antagonists involve the control of the latter stages of aSyn aggregation, thereby preventing the associated neurotoxicity. These findings suggest that A 2A R represent an important target for the development of effective drugs for the treatment of PD and related synucleinopathies.
Introduction
Parkinson's disease (PD) is a progressive and chronic neurodegenerative disorder characterized by the loss of dopaminergic neurons in the "substantia nigra pars compacta", which underlies the classical motor symptoms of the disease (Jankovic 2008 ). Another important neuropathological hallmark of the disease is the presence of intraneuronal inclusions known as Lewy bodies and Lewy neurites (Braak et al. 2003) . These deposits occur early in the disease process and are accompanied by progressive neuronal dysfunction and, eventually, death of the afflicted neuronal populations (Braak and Del Tredici 2008) . Behavioral and cognitive deficits are concomitant with these pathological changes (Turner 2002) . In fact, the accumulation of Lewy bodies and Lewy neurites is not restricted to substantia nigra but is extended to several brain areas including those related to memory, such as the hippocampus and cortex (Spillantini et al. 1997; Mattila et al. 2000; Braak et al. 2004) . Moreover, recent "postmortem" studies in PD patient brains suggest a correlation between cognitive deficits or dementia and the accumulation of cortical Lewy bodies (Kövari et al. 2003; Braak et al. 2005; Caviness et al. 2011) . These inclusions are mainly composed of fibrillar aggregates of α-synuclein, a neuronal presynaptic protein associated with both familial and sporadic forms of PD (Satake et al. 2009; Simón-Sánchez et al. 2009; Hamza et al. 2010) .
Recently, adenosine A 2A receptor (A 2A R) emerged as an attractive nondopaminergic target for the treatment of motor and nonmotor symptoms of PD. Antiparkinsonian actions are achieved through the blockade of this receptor, whose expression and function become aberrant throughout aging and in agerelated pathologies, including the early stages of PD (Lopes et al. 1999; Varani et al. 2010; Villar-Menéndez et al. 2014 ). This strategy was also proven beneficial in other diseases associated with neuronal dysfunction, such as epilepsy, acute and chronic stress and Alzheimer's disease (Cunha 2005; Canas et al. 2009; Batalha et al. 2013; Laurent et al. 2014 ). In addition, epidemiological studies show an inverse correlation between the consumption of caffeine, an A 2A R antagonist, and the risk of developing PD (Ascherio et al. 2001) .
Furthermore, A 2A R deregulation was suggested to play an important role in α-synuclein-mediated neurotoxicity, since α-synuclein-induced damage to striatal neurons was clearly reduced in A 2A R KO mice (Kachroo and Schwarzschild 2012) . However, the extent to which A 2A R are involved in α-synucleinassociated toxicity, the underlying protective molecular mechanisms, or the impact on other brain areas is still unknown. Therefore, the purpose of this study was to gain insight into the novel concept of a crosstalk between α-synuclein and A 2A R and to explore the ability of A 2A R to modulate α-synuclein-mediated synaptic dysfunction, formation of inclusions, and neuronal death. To test these hypotheses, we first assessed the functional outcomes of the pharmacological blockade or genetic deletion of A 2A R on rodent hippocampal slices exposed to extracellular α-synuclein oligomers. Then, we set out to determine how A 2A R affect α-synuclein-mediated cell death, and more importantly, whether modulation of A 2A R function impacts on α-synuclein aggregation and oligomerization.
Here, we show for the first time that selective adenosine A 2A R antagonists rescue both exogenous and endogenous α-synuclein-associated cell death. In addition, we found that A 2A R modulation alters the formation of α-synuclein inclusions in cultured cells. Furthermore, the toxic effects of α-synuclein oligomers on synaptic function are fully prevented by A 2A R blockade or deletion, through a mechanism dependent on NMDA receptor. These findings suggest that A 2A R represent an important target for the development of effective drugs for the treatment of PD and related synucleinopathies.
Materials and Methods

Animals
Animal procedures were performed in accordance with the guidelines of the European Community guidelines (Directive 2010/63/EU), Portuguese law on animal care (1005/92), and approved by the "Instituto de Medicina Molecular" Internal Committee and the Portuguese Animal Ethics Committee ("Direcção Geral de Veterinária"). Environmental conditions were kept constant: food and water ad libitum, 21 ± 0.5°C, 60 ± 10% relative humidity, 12-h light/dark cycles. All animals were killed by decapitation after anesthesia under halothane atmosphere. Male Wistar rats (8-12 weeks old) were purchased from Harlan Interfauna Iberica. Global A 2A R KO mice with a C57Bl/6-background were generated by a standard replacement-type vector constructed to inactivate the A 2A R (Chen et al. 1999) . Congenic global A 2A R KO mice were made by backcrossing KO on mixed (129-Steel × C57BL/6) genetic background to C57BL/6 mice for 13-15 generations. Heterozygous cross-breeding was used to generate WT and global KO mice. Male KO and WT mice with matched age (8-12 weeks old, male) were used for electrophysiological experiments.
Purification and Oligomerization of Recombinant α-Synuclein α-Synuclein was prepared as previously Vicente Miranda et al. 2013) . Monomeric α-synuclein was readily used or stored at −80°C until further use. Oligomerization was induced by continuous shaking of monomeric α-synuclein (140 µM) for 6 days at 37°C in a thermomixer (Eppendorf ) at 900 rpm. Samples were ultracentrifuged to remove fibrillary α-synuclein. The supernatant containing monomeric and oligomeric α-synuclein was centrifuged in Amicon filter unit with Ultracel membrane NMWL of 30 kDa (Millipore). The retained fraction containing α-synuclein oligomers (>30 kDa) was readily used or stored at −80°C until further use. The concentration of α-synuclein was determined using its molar extinction coefficient at 280 nm (i.e., ɛ 280 = 5960 L/mol/cm).
SDS-PAGE
The composition of different α-synuclein species, monomers, and oligomers was evaluated by SDS-PAGE. Five micrograms of each α-synuclein sample was separated by SDS-PAGE using a Tetra Cell (Bio-Rad) in a precast 4-15% polyacrylamide gel (BioRad) using standard procedures. Proteins were transferred to a nitrocellulose membrane (Bio-Rad) using the Mini Tans-Blot system (Bio-Rad).
Prestained standard proteins were also loaded on the gel. Membrane was blocked for 1 h at room temperature (RT) with blocking solution (5% bovine serum albumin in 50 mM Tris, 150 mM NaCl, 0.1% and Tween 20, pH 7.5). The membrane was incubated overnight at 4°C with mouse anti-α-synuclein primary antibody (1:1000; BD Transduction Laboratories) diluted in blocking solution. Membrane was washed and incubated for 1 h at RT with anti-mouse-horseradish peroxide (HRP)-conjugated secondary antibody (1:10 000, Invitrogen) diluted in blocking solution. Detection procedures were performed according to ECL system (Millipore) using a chemidoc system (Bio-Rad).
Rat Primary Neuronal Cultures
Hippocampal neurons were cultured from 18 days Sprague Dawley rat (Harlan, Barcelona, Spain) embryos as previously described (Valadas et al. 2012) . Briefly, embryos were collected in Hank's Balanced Salt Solution (1 mM Ca 2+ and 1 mM Mg 2+ ) and rapidly decapitated. Meninges and white mater were removed, and whole cortices (hippocampi and attached cortex) were incubated for 15 min in Hank's Balanced Salt Solution and 0.025% trypsin. Cells were centrifuged 3 times and washed with Hank's Balanced Salt Solution (10% fetal bovine serum) and finally re-suspended in Neurobasal medium. Cells were plated on poly--lysine-coated coverslips in 24-well plates at density of 8 × 10 4 cells/well. Neurons were grown for 10 days at 37°C in a 5%
CO 2 -humidified atmosphere in Neurobasal medium with 2% B-27 supplement, 25 µm glutamate, 0.5 mm glutamine, and 2 U/mL penicillin/streptomycin, in the absence of any positive selection for neurons. Cells with 9 or 10 DIV were treated with extracellular α-synuclein species (500 nm) for 24 h or 90 min, respectively.
Electrophysiological fEPSPs Recordings
The experiments were performed in acute transverse hippocampal slices from male Wistar rats (8-12 weeks old) and in A 2A R KO and WT mice. After decapitation, the brain was rapidly removed and the hippocampi were dissected free in ice-cold artificial CSF or Krebs solution composed of (mM): NaCl 124; KCl 3; NaH 2 PO 4 1.25; NaHCO 3 26; MgSO 4 1; CaCl 2 2; and D-glucose 10, previously gassed with 95% O 2 and 5% CO 2 , pH 7.4. Slices (400 μm thick) were obtained with a McEwan tissue chopper and were incubated with or without extracellular α-synuclein oligomers (500 nM) for 90 min at RT in gassed artificial CSF. Incubation with SCH 58261 (50 nM) started 20 min prior to α-synuclein oligomers incubation and was kept throughout the 90 min of α-synuclein incubation ( Fig. 2A) . Following this incubation period, slices were superfused with artificial CSF (3 mL/min) at 30.5°C and fEPSPs were recorded as previously in the "stratum radiatum" of the CA1 area. We first carried out input-output (I/O) curves, and then LTP was induced by a theta-burst protocol (10 trains with 4 pulses each at 100 Hz, separated by 200 ms).
SH-SY5Y Cells Inducibly Overexpressing Wild-Type α-Synuclein
Stable SH-SY5Y cell lines inducibly expressing human WT α-synuclein (kind gift from Prof. Kostas Vekrellis, Athens, Greece) were generated as previously described (Vekrellis et al. 2009 ). Cells were cultured in RPMI 1640 ® medium (Life Technologies) supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 mg/mL). SH-SY5Y cells were maintained in 250 µg/mL G418 and 50 µg/mL hygromycin B. α-synuclein expression was switched off by the addition of doxycycline (Dox) (2 µg/mL). Stock cultures were kept in the presence of Dox. Overexpressing α-synuclein cells were maintained for 12 DIV in the absence of Dox. For propidium iodide (PI) and Syto-13 uptake assay cells were plated onto 12-well plates (3.8 cm 2 ) at a density of 6 × 10 4 cells/well, 24 h before drug exposure. For western blot analysis, the cells were seeded into 6-well plates at a density of 15 × 10 4 cells/well.
H4 Cells Stably Expressing VN-Syn/Syn-VC
For the α-synuclein dimerization model, human H4 neuroglioma cells stably expressing 2 α-synuclein BiFC constructs were used (Outeiro et al. 2008 ). This assay is based on the reconstitution of functional fluorescent proteins promoted by the interaction between, at least, 2 α-synuclein molecules, which enables the direct visualization of α-synuclein dimeric/oligomeric species formation. The 2 BiFC constructs used were generated by fusing half of the fluorescent Venus protein with α-synuclein in the N-terminal and the other half fused with α-synuclein in the C-terminal. Cells were maintained in OPTI-MEM ® (Life Technologies) supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 mg/mL) in a humidified atmosphere of 5% of CO 2 in air at 37°C. Cells were plated onto 12-well plates and 24 h before treatment. Twenty-four hours after drug treatment, cells were washed with phosphate buffer saline (PBS: NaCl 137 mM, KCl 2.7 mM, KH 2 PO 4 1.8 mM and Na 2 HPO 4 10 mM, pH 7.4) and fixed with 4% paraformaldehyde (PFA) for 10 min at RT, followed by a 10 min incubation with Hoescht 33258 dye (1 mg/mL, Life Technologies-Invitrogen) at RT. Cells were then washed and maintained in PBS and imaged on an Olympus IX81-ZDC microscope system (Olympus Germany) using the 20× objective and maintaining the same exposure time for Venus and Hoechst channels for each condition. Quantification of the number of cells and average Venus fluorescence intensity was performed using an in-house developed macro for ImageJ (http ://imagej.nih.gov/ij/). Briefly, single-cell nuclei were identified using the Hoechst channel by thresholding and particle analysis, and the corresponding regions of interest (ROIs) were then used to measure the average intensity in the Venus channel. The number of cells with α-synuclein dimers was determined by counting the ROIs where the average fluorescent intensity was higher than a given threshold. Values of each condition were then averaged and statistical analysis was performed.
Human Neuroglioma H4 Cells
Human neuroglioma H4 cells were maintained in OPTI-MEM ® (Life Technologies) supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 mg/mL) in a humidified atmosphere of 5% of CO 2 in air at 37°C. Cells were plated in 12-well plates 24 h prior to transfection. Cells were transfected with equimolar amounts of the plasmids encoding the human WT α-synuclein with a C-terminal tag corresponding to a truncated fragment of EGFP (referred to as SynT) and synphilin-1 as previously (Lázaro et al. 2014) . Twenty-four hours after transfection, the cells were incubated for 24 h with different A 2A R modulators and, after this period, the cells were subjected to immunocytochemistry for studying α-synuclein inclusions. Transfected cells were identified and classified in 2 groups: cells without inclusions and cells with one or more inclusions. Results were expressed as the percentage of the total number of transfected cells.
Immunocytochemistry
Forty-eight hours after transfection, H4 cells were washed with PBS and fixed with 4% PFA for 10 min at RT, followed by a permeabilization step with 0.5% Triton X-100 (Sigma-Aldrich) for 20 min at RT. After blocking in 1.5% normal goat serum (PAA)/ DPBS for 1 h, the cells were incubated with mouse anti-α-synuclein primary antibody (1:1000, BD Transduction Laboratories) overnight at 4°C. After a 30-min washing with PBS, the cells were incubated with the secondary antibody Alexa Fluor 488 donkey anti-mouse IgG (Life Technologies-Invitrogen) for 2 h at RT. Finally, the cells were stained with Hoechst 33258 (1 mg/mL, Life Technologies-Invitrogen) (1:5000 in DPBS) for 10 min and maintained in PBS for epifluorescence microscopy.
Propidium Iodide and Syto-13 Uptake Assay
This protocol was used either in primary neuronal cultures or SH-SY5Y cells and performed as previously described (Valadas et al. 2012) . Briefly, cells were washed with Krebs-HEPES (NaCl 117 mM, KCl 3 mM, glucose 10 mM, NaHCO 3 26 mM, Na 2 HPO 4 1.25 mM, HEPES 10 mM, CaCl 2 2 mM, MgCl 2 1 mM), incubated with Syto-13 (4 µM) and PI (5 µg/mL) for 3 min at RT and directly observed using an Axiovert 200 fluorescence microscope. An average of 1400 cells were counted per condition in each experiment. Syto-13 labels with green fluorescence (emits preferentially at 509 nm when excited at 488 nm) both RNA and DNA in living cells. PI labels with red fluorescence (absorbing preferentially at 535 nm and emitting at 617 nm) cells that lost plasma membrane integrity. Cell viability was presented as the ratio between the number of living cells and the total number of cells.
Real-Time qPCR
Total RNA from H4 and SH-SY5Y cells was extracted using the RNAspin Mini RNA isolation kit (GE Healthcare). Briefly, cell cultures were washed with PBS, scraped, collected in lysis buffer and processed according to the manufacturer's instructions. RNA was quantified with the NanoDrop 2000 (Thermo scientific). Total RNA (2 μg) was reverse-transcribed using random primers and SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen, Life technologies), and negative controls were made without reverse transcriptase. qPCR was carried out with Power SYBR Green PCR Master mix (Applied Biosystems), using 8 ng/µL of total cDNA and 0.2 µm of each primer, performed in a RotorGene 6000 Real Time Rotary Analyzer (Corbett Research). The thermal cycler conditions were 10 min at 95°C, 40 cycles of a two-step PCR, 95°C for 15 s followed by 60°C for 25 s with a final thermal ramp from 72 to 95°C. The primers used in qPCR include: forward 5′-AACCTGCAGAACGTCAC-3′ and reverse 5′-GTCACCAAGCCA TTGTACCG-3′ for human A 2A R (Invitrogen, HPLC purified, product size 245 bp) and forward 5′-GGACTTCGAGCAAGAGATGG-3′ and reverse 5′-AGCACTGTGTTGGCGTACAG-3′ for human β-actin (Invitrogen, HPLC purified, product size 233 bp). The qPCR products were analyzed by electrophoresis on a 2% agarose gel containing Greensafe Premium Nucleic Acid Gel Stain (Nzytech).
Co-immunoprecipitation (Co-IP)
Briefly, WT rat hippocampal slices were homogenized in IP buffer (NP40 1%, SDS 0.1%, Tris-HCl 50 mM, NaCl 150 mM, sodium deoxycholate 0,5%, EDTA 1 mM, protease inhibitors-Complete, EDTA-free Protease Inhibitor cocktail tablets; Roche). Protein extracts were incubated with protein G PLUS-Agarose (Santa Cruz Biotechnology) for 1 h at 4°C to eliminate nonspecific binding. After incubation, the precleared supernatants containing 1 mg of protein were incubated with anti-PSD-95 antibody (1:50; Cell Signaling Technology) or IgG (for negative control; Santa Cruz Biotechnology) overnight at 4°C under rotation. The day after, lysates were incubated with protein G PLUS-Agarose for 3 h with rotation at 4°C. Beads were washed 3 times with IP buffer and resuspended in 1.5× sample buffer pH (Tris 359 mM pH 6.8, glycerol 30%, sodium dodecyl sulfate 10%, dithiothreitol 600 mM, and bromophenol blue 0.012%). Bound proteins eluted from the immune complexes were denatured by heating to 95°C for 5 min and used for western blot analysis. Western blot was performed with anti-NMDA receptor subunit 2B (1:1000; Cell Signaling technology), anti-NMDA receptor subunit 1 (1:500; BD Pharmingen™), and anti-PSD-95 (1:1000; Cell Signaling Technology) (see western blot).
Western Blotting
SH-SY5Y cells were washed with cold PBS and then mechanically scrapped in radioimmunoprecipitation assay buffer pH 8.0 (RIPA buffer: NaCl 150 mM, Tris-base 50 mM, EDTA 1 mM, Nonidet P40 1%, sodium dodecyl sulfate 0.1%, proteases inhibitors-Complete, EDTA-free Protease Inhibitor cocktail tablets; Roche).
Cells were centrifuged at 16 000×g during 10 min at 4°C and the pellet, including cell debris, was discarded and the supernatant used for western blot. After protein quantification using BioRad DC Protein Assay kit, lysates were denatured with 5× sample buffer pH 6.8 (Tris 359 mM pH 6.8, glycerol 30%, sodium dodecyl sulfate 10%, dithiothreitol 600 mM, and bromophenol blue 0.012%) and heated at 95°C for 5 min and further processed as before (Valadas et al. 2012) . Samples and the prestained molecular weight marker (BIO-RAD) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 15% gel) under reducing conditions and electro-transferred to polyvinylidene difluoride membranes (0.45 µm, Immobilon) using standard procedures. Thereafter, nonspecific binding was blocked with 3% bovine serum albumin (fatty acid free) in Tris-buffered saline ( pH 7.6) containing 0.1% Tween 20 (TBS-T) for 1 h at RT. Membranes were then incubated overnight at 4°C with the corresponding primary antibody, namely mouse anti-α-synuclein (1:1000; BD transduction lab), mouse anti-adenosine A 2A R (1:1000; Millipore), rabbit anti-α-tubulin (1:5000; Abcam), mouse anti-GAPDH (1:1000; Ambion), rabbit anti-PSD-95 (1:1000; Cell Signaling), rabbit anti-NMDA receptor subunit 2B (1:1000; Cell Signaling), mouse anti-NMDA receptor subunit 1 (1:500; BD Pharmingen™) diluted in blocking solution. After 3 washing periods of 10 min with TBS-T, membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary antibodies (1:10 000; Santa Cruz Biotechnology) (in 5% nonfat dry milk) for 1 h at RT. After 40 min of washing with TBS-T, chemiluminescent detection was performed with ECL western blotting detection reagent (GE Healthcare) using X-Ray films (Fujifilm). Densitometric quantification was determined using Image-J software and normalized to the corresponding α-tubulin band density. 1,3-Dipropyl-8-cyclopentyladenosine (DPCPX; Tocris Cookson) was prepared as a 5 mM stock solution in 99% DMSO and 1% NaOH 1 M. DL-2-Amino-5-phosphonopentanoic acid (APV; Abcam) was prepared as a 100 mM stock solution in NaOH 100 mm. All aliquots were kept frozen at −20°C until use.
Statistics
The values presented are mean ± SEM of n independent experiments. To test the significance of the differences between 2 conditions, a Student's t test was used. In statistical tests between 3 or more conditions, a one-way ANOVA followed by a Bonferroni's multiple comparison post hoc test was used. P-values of <0.05 were considered to be statistically significant.
Results
A 2A R Blockade Rescues Neuronal Cell Death Induced by Exogenous α-Synuclein Oligomers
First, we compared the effect of different α-synuclein species on rat primary hippocampal cultures. Cells were incubated with either monomeric or oligomeric α-synuclein preparations for different time periods. The confirmation of the biochemical properties of the different species was performed by SDS-PAGE/ immunoblot analysis, revealing that monomers migrated with a typical molecular weight of ∼ 15 kDa (monomeric molecular weight of α-synuclein), whereas oligomeric forms migrated with an apparent molecular weight of >30 and <180 kDa (Fig. 1D) . We found no significant cytotoxicity in cells treated with either α-synuclein species (500 nM) for 90 min, as assessed by PI and Syto-13 staining. Conversely, we found that after 24 h of exposure there was a robust increase in neuronal cell death upon incubation with α-synuclein oligomers (cell viability CTR = 68.7 ± 4.6%; cell viability aSyn olig, 24h = 35.5 ± 3.1%; n = 4; *P < 0.001; Fig. 1A ,B), whereas monomeric species had no effect on cell viability. We next investigated whether adenosine A 2A R blockade could attenuate the neurotoxic effects induced by exposure to α-synuclein oligomers. The blockade of A 2A R, using the selective antagonists SCH 58261 (50 nM) or ZM 241385 (50 nM), significantly reduced neuronal cell death induced by α-synuclein oligomers, resulting in levels similar to control (cell viability SCH 58261 + aSyn olig, 24 h = 70.6 ± 4.3%; cell viability ZM 241385+ aSyn olig, 24 h = 69.7 ± 3.2%, n = 4; *P < 0.001 vs. CTR; Fig. 1A,C) .
Pharmacological or Genetic Blockade of A 2A R Prevents LTP Impairment Induced by α-Synuclein Oligomers
We have previously demonstrated that α-synuclein oligomers, but not monomers or fibers, impair synaptic plasticity and increase basal synaptic transmission through NMDA receptor activation ). Thus, we next set out to investigate the role of A 2A R on this impairment of synaptic function. For this, we preincubated rat hippocampal slices with α-synuclein oligomers together with the selective A 2A R antagonist SCH 58260 (50 nM, 110 min; Fig. 2A ) and induced LTP in Schaffercollaterals/CA1 pyramid glutamatergic synapses by theta-burst stimulation. The LTP amplitude was significantly reduced in slices preincubated with α-synuclein oligomers (500 nM, 90 min) when compared with control slices (LTP CTR = 58.1 ± 7.4%; LTP aSyn olig = 7.7 ± 2.3%; n = 9; *P < 0.001; Fig. 2B-D) . When A 2A R were blocked by SCH 58261, the LTP magnitude was reestablished to control values (LTP SCH 58261 + aSyn olig = 50.6 ± 13.0%; n = 5; *P < 0.01 vs. LTP aSyn olig ; Fig. 2B-D) . SCH 58261 alone did not affect LTP magnitude (LTP SCH 58261 = 52.5 ± 10.6%; n = 5; *P < 0.05 vs. LTP CTR ; Fig. 2D) .
To assess the role of A 2A R on NMDA receptor-mediated effects, we evaluated the effect of the NMDA receptor antagonist APV (50 µM) on basal synaptic transmission. As expected, APV did not modify the fEPSP slope in control slices (Fig. 2E,F) . In contrast, the acute application of APV induced a progressive reduction of the fEPSP in α-synuclein oligomer-treated slices (fEPSP aSyn olig = −13.5 ± 1.8%; n = 7; *P < 0.001; Fig. 2E,F) , in agreement with the previously reported impact of oligomeric α-synuclein on NMDA receptor . Interestingly, when slices were preincubated with SCH 58261 together with α-synuclein oligomers, the effect of the NMDA receptor antagonist was prevented (fEPSP SCH 58261 + aSyn olig = −6.4 ± 1.3%; n = 6; *P < 0.05 vs. fEPSP aSyn olig ; Fig. 2E,F) . Accordingly, we observed an increase in NMDA receptor subunit 2B (NMDAR2B 137.4 ± 4.3%; n = 4; *P < 0.05 vs. CTR; Fig. 2H ) in slices exposed to α-synuclein, but not in NMDA subunit 1 (NMDAR1). This increase was prevented by co-incubation with SCH 58261 (101.9 ± 8.3%; n = 3; *P < 0.05 vs. CTR; Fig. 2H ). SCH 58261 alone did not alter NMDA receptor subunit 2B levels. In order to evaluate whether A 2A R blockade also rescued baseline synaptic efficiency, I/O curves were recorded. Slices preincubated with α-synuclein oligomers alone showed a shift to the left in the I/O curve, as previously described . SCH 58261 co-incubation did not change this α-synuclein-induced effect (Fig. 2G) .
We then assessed the synaptotoxic effects of α-synuclein oligomers on hippocampal slices from A 2A R KO mice. Remarkably, α-synuclein oligomers (500 nM, 90 min) failed to impair LTP in A 2A R KO mice (LTP CTR = 34.3 ± 6.9%; LTP aSyn olig = 31.2 ± 4.2%; n = 3; *P < 0.05; Fig. 3D,E) , in contrast to the significant effect in WT mice (LTP CTR = 64.4 ± 14.2%, n = 4; LTP aSyn olig = 10.9 ± 12.9%; n = 3; *P < 0.05; Fig. 3A,B) . As observed in rat hippocampal slices, α-synuclein oligomers also increased basal synaptic excitability, as observed by the shift to the left of the I/O curve, both in WT and A 2A R KO mice (Fig. 3C,F) .
A 2A R Blockade Rescues Cell Death Induced by Endogenous α-Synuclein
To evaluate the role of A 2A R on the toxicity induced by intracellular α-synuclein, we used an established Dox inducible (tet-off ) neuroblastoma cell model that we verified to express A 2A R (Supplementary Fig. 1A ). Maximal α-synuclein expression was reached at 12 days after Dox removal (Supplementary Fig. 1B ) and, at this time point, we found a significant decrease in cell viability compared with control cells in the presence of Dox (+Dox) (cell viability +Dox CTR = 91.6 ± 1.5%; cell viability -Dox CTR = 68.7 ± 1.6%; n = 8-9; *P < 0.001; Fig. 4A,B) ; the A 2A R mRNA or protein levels were not altered (Supplementary Fig. 1C,D) . This toxicity was completely prevented by a 24-h treatment with the selective A 2A R antagonists, SCH 58261 or ZM 241385 (cell viability −Dox + SCH 58261 = 87.1 ± 5.1%; cell viability −Dox + ZM 241385 = 84.8 ± 5.5%; n = 4-7; *P < 0.01 vs. +Dox CTR; Fig. 4A,B) . Furthermore, activation of A 2A R with the selective A 2A R agonist CGS 21680 (30 nm) in control cells in the presence of Dox resulted in cytotoxicity, mimicking α-synuclein overexpression (−Dox CTR) (Fig. 4C) . Importantly, these effects were not due to changes in α-synuclein levels induced by the different treatments ( Supplementary Fig. 1E ). Next, we investigated whether NMDA receptors were involved in this effect. When NMDA receptors were blocked by APV alone, the toxicity induced by overexpression of α-synuclein (−Dox) was completely rescued (cell viability −Dox + APV = 92.5 ± 1.7%; n = 4; *P < 0.001 vs. −Dox CTR; Fig. 4A,C) . This effect is the same of that observed upon A 2A R blockade. Consistently, blockade of NMDA receptor also prevented toxicity induced by direct A 2A R activation with CGS 21680 (Fig. 4A,C) .
To rule out any possible contribution of the more abundant adenosine receptor, A 1 receptor (A 1 R), to the α-synuclein-induced effects, we selectively blocked this receptor (DPCPX, 50 nM).
DPCPX alone (50 nM) reduced cell viability by 20%, as expected (Valadas et al. 2012) . A 1 R are not involved in α-synuclein-induced toxicity since this reduction was similar in either +Dox or −Dox cells (Fig. 4D) . Moreover, the effect of A 2A R activation by CGS 21680 is independent of A 1 R, being maintained even under A 1 R blockade (+Dox + DPCPX+CGS 21680). Finally, the increase in cell viability achieved by A 2A R blockade (ZM 241385) in −Dox cells is still present even under A 1 R blockade (Fig. 4D) . 
A 2A R Blockade Does not Affect α-Synuclein Oligomerization
We next evaluated whether A 2A R affected the initial events of α-synuclein aggregation, by monitoring the ability of α-synuclein to oligomerize, using a stable cell model of α-synuclein dimerization/oligomerization based on BiFC (Outeiro et al. 2008) (Fig. 5A) . We found that α-synuclein formed oligomers in H4 control cells (CTR; Fig. 5C ), and no significant differences in the oligomerization pattern were detected upon A 2A R modulation, as assessed by Venus fluorophore reconstitution (Fig. 5B,C) . This lack of effect does not stem from a reduced dynamic range, as we have previously validated the reversibility of the system in response to multiple conditions (Outeiro et al. 2008; Zondler et al. 2014) .
A 2A R Blockade Decreases α-Synuclein Aggregation
Finally, we asked whether A 2A R affected latter steps in the process of α-synuclein aggregation. For this, we used an established model of α-synuclein inclusion formation in human neuroglioma H4 cells (McLean et al. 2001; Lázaro et al. 2014 ) that also express A 2A R (Fig. 6C,D) . We found that a 24-h treatment with the A 2A R antagonist ZM 241385 (50 nM) significantly reduced the percentage of cells displaying α-synuclein inclusions (α-synuclein inclusions CTR = 70.3 ± 2.0%; α-synuclein inclusions ZM 241385 = 58.4 ± 4.2%, n = 3-4; *P < 0.05; Fig. 6A,B) . In contrast, activation of A 2A R with CGS 21680 (30 nM) increased the percentage of cells containing α-synuclein inclusions (α-synuclein inclusions CGS 21680 = 83.8 ± 1.1%, n = 3; *P < 0.05 vs. α-synuclein inclusions CTR ; Fig. 6A ,B).
Discussion
We have gathered evidence indicating that A 2A R play an important role in modulating the deleterious effects of α-synuclein. Here, we show, for the first time, that selective A 2A R antagonists are able to rescue both exogenous and intracellular α-synuclein-mediated cyto-and neurotoxicity. Furthermore, pharmacological and genetic inactivation of A 2A R fully prevents the α-synucleinmediated toxic effects on synaptic function. This neuroprotective effect afforded by A 2A R inhibition is due to the reestablishment of glutamate NMDA receptor signaling. Finally, we found that A 2A R antagonists are also able to decrease the number of α-synuclein aggregates, which might explain their protective effects on α-synuclein-associated synaptic dysfunction and neuronal death. α-Synuclein aggregation and progressive neuronal cell death are the neuropathological hallmarks of several neurodegenerative disorders known as synucleinopathies (Marques and Outeiro 2012) . However, the precise molecular mechanisms underlying the process of α-synuclein aggregation and the exact nature of the toxic species produced during aggregation remain unclear. α-Synuclein is a soluble protein expressed ubiquitously in the central nervous system, including the cerebral cortex, hippocampus, amygdala, and olfactory bulb (Maroteaux and Scheller 1991; Abeliovich et al. 2000) . Under pathological conditions, this protein exhibits a propensity to misfold and aggregate, first into small oligomeric species that are rich in β-sheet structure, and then into higher-molecular-weight insoluble fibrils (Spillantini et al. 1998; Lashuel et al. 2012) . As reported for amyloid-beta plaques in Alzheimer's disease, soluble oligomeric species are thought to constitute the most neurotoxic species (Kayed et al. 2003; Glabe and Kayed 2006; Irvine et al. 2008; Outeiro et al. 2008; Emadi et al. 2009; Martin et al. 2012 ). Consistently, we observed that mature extracellular α-synuclein oligomers have the ability to induce synaptic impairment through an NMDA receptor-dependent mechanism . We now report that exposure to α-synuclein oligomers causes damage in primary neuronal cultures, ultimately leading to neuronal death. In contrast, α-synuclein monomers have no effect.
An imbalance in adenosine levels in the brain together with an abnormal function and increased A 2A R levels, which facilitates excitotoxicity and consequent neuronal death, has been reported in multiple conditions such as ischemia, stress, epilepsy, Alzheimer's and PD (Lopes et al. 1999; Latini and Pedata 2001; Rebola et al. 2005; Cunha et al. 2006; Varani et al. 2010; Batalha et al. 2013; Villar-Menéndez et al. 2014) . Based on this idea, A 2A R antagonists started emerging as promising candidates in modulating the demise of different psychiatric and neurological disorders, including PD. In fact, it was demonstrated that consumption of caffeine, a nonspecific A 2A R antagonist, reduces the risk of developing PD (Ascherio et al. 2001) . Indeed, polymorphisms in the human A 2A R gene (ADORA2A) are linked to a reduced risk of PD (Popat et al. 2011) . The specific blockade of these receptors was shown to be protective in several PD models (Chen et al. 2001; Ikeda et al. 2002; Aguiar et al. 2006; Kachroo et al. 2010; Xu et al. 2010 ); including in α-synuclein-mediated neurotoxicity (Kachroo and Schwarzschild 2012) . The crossing of A 2A KO with hm 2 -α-synuclein mice resulted in reduced neuronal loss, suggesting the potential involvement of A 2A R on α-synuclein-associated toxicity. However, in this report, the impact of A 2A R on α-synuclein oligomerization or aggregation was not determined (Kachroo and Schwarzschild 2012) . In order to clarify the molecular basis of A 2A R-mediated protection against α-synuclein toxicity, we now evaluated the A 2A R effect in multiple models of α-synuclein aggregation and toxicity. Our data demonstrate that the selective blockade or deletion of A 2A R prevents both synaptic plasticity impairment and neuronal death induced by extracellular α-synuclein oligomers. The ability to respond to theta-burst stimulation, when exposed to α-synuclein mature oligomers, is restored either in hippocampal slices from A 2A R KO mice, or WT slices in the presence of a specific A 2A R antagonist. As we have previously reported, α-synuclein oligomers promote an increase in basal synaptic transmission both by the activation of NMDA receptor and by the insertion of Ca 2 + -permeable AMPA receptors in the postsynaptic membrane , which leads to synapse saturation and consequent LTP impairment. Since Ca 2+ -permeable AMPA receptors are crucial for LTP maintenance (Plant et al. 2006) , the complete rescue of LTP impairment by A 2A R antagonist suggests a reestablishment of this AMPA impaired trafficking. In fact, it has been described that A 2A R have the ability to modulate the membrane levels of Ca
2+
-permeable AMPA receptors , which can explain the observed effects. Furthermore, we show that the basal overactivation of NMDA receptor caused by α-synuclein oligomers is also prevented by A 2A R blockade, since NMDA receptor basal contribution is no longer observed. However, while glutamatergic transmission is restored, the effects of α-synuclein on basal synaptic transmission were not rescued by A 2A R blockade or in A 2A R KO mice, as reflected in the unmodified steeper I/O curve. A 2A R do not only affect glutamatergic transmission, but can also directly enhance inhibitory GABAergic transmission, leading to disinhibition of pyramidal cells (Rombo et al. 2014) . A possible explanation for the lack of effect of A 2A R blockade on the I/O curve might be due to a resulting overall excitation, caused by a decrease in the inhibitory GABAergic tonus.
In addition to these effects in early synaptic dysfunction, A 2A R antagonists were also effective in preventing subsequent neuronal death in neuronal cultures exposed to α-synuclein oligomers. Our observations are consistent with previous reports showing that pharmacologic or genetic modulation of A 2A R can prevent neurotoxicity and the extent of neuronal damage in neurons affected by ischemia, hypoxia, stress, or β-amyloid exposure (Cunha 2005; Canas et al. 2009; Valadas et al. 2012) . To further detail the mechanism of A 2A R action on α-synuclein-induced toxicity, we used an established SH-SY5Y cell model of endogenous α-synuclein accumulation (Vekrellis et al. 2009 ). Cells overexpressing α-synuclein for 12 DIV show increased cell death that is rescued by selective A 2A R antagonists. Furthermore, if we activate A 2A R in control cells (+Dox), we mimic the cytotoxic effects induced by α-synuclein accumulation (−Dox), supporting the idea of the involvement of A 2A R overactivation on α-synuclein-induced cell death. Together, these data raises the hypothesis that α-synuclein accumulation is leading to a toxic overactivation of A 2A R. This can result either from, overexpression of A 2A R in these conditions or, alternatively, to an increase of the endogenous ligand adenosine. The fact that the overexpression of α-synuclein does not alter A 2A R levels favors the latter hypothesis. Under physiological conditions, adenosine is tonically activating the abundant A 1 R and producing synaptic inhibition (Dunwiddie and Diao 1994; Takahashi et al. 1995; Dittman and Regehr 1996) . However, in this situation, A 1 R do not seem to contribute to α-synuclein-induced toxicity, since when we blocked the receptors, we could not see any differences in cell viability upon α-synuclein accumulation. This is in accordance with different sources of adenosine activating A 1 R and A 2A R (Cunha 2008) .
Together our results suggest that α-synuclein-induced cell death is associated with an increase in A 2A R activation that mediates NMDA receptor overactivation, which is a prominent synaptic event leading to excitotoxicity (Besancon et al. 2008) . In fact, A 2A R are known to increase NMDA receptor function in the hippocampus , namely promoting Ca 2+ entry through NMDA receptor, by (PKA)-dependent regulation (Higley and Sabatini 2010) . Interestingly, the same mechanisms of Ca 2+ entry dysfunction (Martin et al. 2012 ) and NMDA receptor activation ) are involved in α-synuclein-associated neurotoxicity. This suggests that A 2A R blockade is probably counteracting these α-synuclein-associated effects, which then translates into the prevention of synaptic dysfunction and cell death. While non-neuronal A 2A R have been implicated in neurotoxinbased PD mechanisms (such as MPTP or 6-OHDA) (Yu et al. 2008) , forebrain neuronal A 2A R are critical for the control of cortico-striatal synaptic activity. Our data reinforce the notion that counteracting neuronal A 2A R activation has benefits, specifically against aSyn-induced synaptic deficits. Furthermore, dysfunction in Ca 2+ has also been shown to increase α-synuclein propensity to form aggregates (Rcom-H'cheo-Gauthier et al. 2014) which are known to be associated with PD-related neurotoxicity (Conway et al. 2000; Karpinar et al. 2009 ). Based on these findings, we hypothesized that the observed protective effects of A 2A R blockade could be due to the modulation of α-synuclein aggregation process, as also observed to occur for the formation of mutated ataxin-3 aggregates (Gonçalves et al. 2013) . To this end, we used 2 cell-based models mimicking different steps of the α-synuclein aggregation process namely dimerization/oligomerization and inclusions formation (McLean et al. 2001 (McLean et al. , 2002 Outeiro et al. 2008 ). We did not detect significant differences in the oligomerization pattern using the BiFC assay, upon treatment with A 2A R modulators. Since this assay does not distinguish between dimers, trimers and highermolecular-weight α-synuclein oligomers (Outeiro et al. 2008) , we cannot discard the hypothesis that A 2A R modulators might interfere with the later stages of aggregation. Indeed, A 2A R blockade decreases the number of α-synuclein inclusions in a cell model of α-synuclein inclusion formation, whereas their activation enhances inclusion formation. It has been reported that the activation of NMDA receptor can downregulate the ubiquitin proteasome system (Caldeira et al. 2013) , which may consequently lead to the accumulation of proteins that are prone to aggregation, like α-synuclein. There are reports suggesting that A 2A R can directly bind and modulate the activity of ubiquitin proteasome system (Milojevic et al. 2006; Chiang et al. 2009 ). The observed changes are not associated with A 2A R affecting directly the levels of aSyn, in accordance with previous observations from Kachroo et al. (2012) . In that study, the authors did not assess changes in the aggregation pattern. Here, we now report for the first time that the A 2A R blockade reduces the percentage of cells containing inclusions, using a very sensitive model that allows more accurate quantifications. Our results suggest that A 2A R modulation does not interfere with the initial events leading to the formation of oligomeric species but, instead, may interfere with the latter stages of the α-synuclein aggregation process. Moreover, these data strongly suggest that the recently reported ability of caffeine (a nonselective adenosine receptor antagonist) to interfere with α-synuclein aggregation might be due to its actions on A 2A R (Kardani and Roy 2015) . Whether these effects are due to the attenuation of ubiquitin proteasome system dysfunction or to downstream mediators of α-synuclein toxicity remains to be clarified. Currently, there are multiple specific A 2A R antagonists, including caffeine, progressing through Phase II and III clinical trials for the symptomatic treatment of PD (Barkhoudarian and Schwarzschild 2011) . Thus, this class of agents is well positioned for clinical testing of their neuroprotective potential. The present findings strengthen the rationale for disease modification trials of A 2A R antagonism and complement epidemiological data on caffeine links to a reduced risk of PD and substantially broaden the potential use of A 2A R as therapeutic targets in synucleinopathies.
Overall, our results highlight the interplay between toxic and protective influences of A 2A R on α-synuclein aggregation and associated synaptic toxicity and neurodegeneration, raising the possibility that adenosine A 2A R antagonists produce their welldocumented neuroprotective effects in PD models by preventing α-synuclein-inclusion formation and consequent associated toxicity. Furthermore, we now show that this rescue in α-synucleinassociated toxicity is being mediated via NMDA receptor, which are known to be involved in proteasome clearance system. Moreover, we also demonstrate that both intracellular overexpression of α-synuclein and extracellular addition of oligomeric α-synuclein increase cell death, suggesting that α-synuclein may induce similar toxic effects irrespective of being generated intra-or extracellulary and, more importantly, A 2A R antagonists are able to completely rescue these α-synuclein-associated toxic events.
